Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis

被引:167
作者
Weigelt, Britta [1 ]
Kreike, Bas [2 ]
Reis-Filho, Jorge S. [3 ]
机构
[1] Ernest Orlando Lawrence Berkeley Natl Lab, Div Life Sci, Berkeley, CA 94720 USA
[2] Netherlands Canc Inst, Amsterdam, Netherlands
[3] Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England
关键词
Microarrays; Expression profile; Basal-like; Epithelial to mesenchymal transition; Breast cancer; SQUAMOUS-CELL CARCINOMA; MOLECULAR PORTRAITS; IDENTIFICATION; EXPRESSION; SUBTYPE; MARKER; EGFR; OVEREXPRESSION; AMPLIFICATION; FEATURES;
D O I
10.1007/s10549-008-0197-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Metaplastic breast carcinomas (MBCs) comprise a group of aggressive and chemotherapy resistant cancers characterised by neoplastic cells displaying differentiation towards squamous epithelium or mesenchymal elements. Previous histopathological and immunohistochemical analysis of MBCs suggested that these cancers would have a basal-like profile. Methods We investigated the molecular subtype of 20 MBCs using microarray-based expression profiling data. These data were compared with those of 79 invasive ductal carcinomas (IDCs) of basal-like phenotype by unsupervised hierarchical clustering, supervised analysis and pathway analysis. Results We demonstrate that 95% of all MBCs are of basal-like molecular subtype. Furthermore, unsupervised hierarchical clustering analysis and pathway analysis of the profiles of MBCs revealed that MBCs are part of the spectrum of basal-like breast cancers. Significance analysis of microarrays (SAM) identified 1,385 transcripts differentially expressed between MBCs and IDCs of basal-like phenotype. Pathway analysis using these genes revealed that DNA repair pathways, including BRCA1 pathway, PTEN, a gene whose loss of function is associated with resistance to chemotherapy, and TOP2A, the molecular target of anthracyclines, are significantly downregulated in MBCs compared to basal-like IDCs. These findings may at least in part explain the reported poor responses to chemotherapy of MBCs. Furthermore, MBCs showed significantly higher expression of genes related to myoepithelial differentiation and epithelial to mesenchymal transition (EMT). Conclusions Our results demonstrate that MBCs are part of the spectrum of basal-like breast carcinomas and display a myoepithelial and EMT-like molecular make-up. The reported poorer response to chemotherapeutic agents in patients with MBCs may stem from downregulated DNA damage response pathways, PTEN and TOP2A.
引用
收藏
页码:273 / 280
页数:8
相关论文
共 53 条
  • [1] Prospective identification of tumorigenic breast cancer cells
    Al-Hajj, M
    Wicha, MS
    Benito-Hernandez, A
    Morrison, SJ
    Clarke, MF
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (07) : 3983 - 3988
  • [2] A synthetic lethal therapeutic approach: Poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair
    Ashworth, Alan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (22) : 3785 - 3790
  • [3] KIT is highly expressed in adenoid cystic carcinoma of the breast, a basal-like carcinoma associated with a favorable outcome
    Azoulay, S
    Laé, M
    Fréneaux, P
    Merle, S
    Al Ghuzlan, A
    Chnecker, C
    Rosty, C
    Klijanienko, J
    Sigal-Zafrani, B
    Salmon, R
    Fourquet, A
    Sastre-Garau, X
    Vincent-Salomon, A
    [J]. MODERN PATHOLOGY, 2005, 18 (12) : 1623 - 1631
  • [4] Cluster analysis and display of genome-wide expression patterns
    Eisen, MB
    Spellman, PT
    Brown, PO
    Botstein, D
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (25) : 14863 - 14868
  • [5] PATHOLOGICAL PROGNOSTIC FACTORS IN BREAST-CANCER .1. THE VALUE OF HISTOLOGICAL GRADE IN BREAST-CANCER - EXPERIENCE FROM A LARGE STUDY WITH LONG-TERM FOLLOW-UP
    ELSTON, CW
    ELLIS, IO
    [J]. HISTOPATHOLOGY, 1991, 19 (05) : 403 - 410
  • [6] Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast
    Fulford, L. G.
    Easton, D. F.
    Reis-Filho, J. S.
    Sofronis, A.
    Gillett, C. E.
    Lakhani, S. R.
    Hanby, A.
    [J]. HISTOPATHOLOGY, 2006, 49 (01) : 22 - 34
  • [7] Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy
    Gilbert, Judith A.
    Goetz, Matthew P.
    Reynolds, Carol A.
    Ingle, James N.
    Giordano, Karin F.
    Suman, Vera J.
    Blair, Hilary E.
    Jenkins, Robert B.
    Lingle, Wilma L.
    Reinholz, Monica M.
    Adiei, Alex A.
    Ames, Matthew M.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2008, 7 (04) : 944 - 951
  • [8] ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome
    Ginestier, Christophe
    Hur, Min Hee
    Charafe-Jauffret, Emmanuelle
    Monville, Florence
    Dutcher, Julie
    Brown, Marty
    Jacquemier, Jocelyne
    Viens, Patrice
    Kleer, Celina G.
    Liu, Suling
    Schott, Anne
    Hayes, Dan
    Birnbaum, Daniel
    Wicha, Max S.
    Dontu, Gabriela
    [J]. CELL STEM CELL, 2007, 1 (05) : 555 - 567
  • [9] Hamperl H, 1970, Curr Top Pathol, V53, P161
  • [10] Biphasic metaplastic sarcomatoid carcinoma of the breast
    Hennessy, BT
    Giordano, S
    Broglio, K
    Duan, Z
    Trent, J
    Buchholz, TA
    Babiera, G
    Hortobagyi, GN
    Valero, V
    [J]. ANNALS OF ONCOLOGY, 2006, 17 (04) : 605 - 613